Blair William & Co. IL Cuts Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Blair William & Co. IL trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 8.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 134,969 shares of the company’s stock after selling 12,921 shares during the quarter. Blair William & Co. IL owned 0.16% of CRISPR Therapeutics worth $7,290,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Global Trust Asset Management LLC raised its stake in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares during the period. Larson Financial Group LLC increased its holdings in CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC raised its position in CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after acquiring an additional 307 shares during the period. Riggs Asset Managment Co. Inc. boosted its stake in CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares during the last quarter. Finally, Principal Securities Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $41,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRSP has been the topic of a number of research reports. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Barclays dropped their price target on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. Truist Financial decreased their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Needham & Company LLC dropped their price objective on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Chardan Capital cut their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus price target of $75.63.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $48.18 on Friday. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10. The company has a market capitalization of $4.09 billion, a P/E ratio of -17.71 and a beta of 1.68. The firm’s 50 day simple moving average is $50.45 and its 200 day simple moving average is $57.16.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.98) EPS. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.6 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.